Transport of six tyrosine kinase inhibitors: active or passive?

Authors

  • Richard J. Honeywell Vrij University medical center, amsterdam
  • Sarina Hitzerd
  • Ietje Kathmann
  • Godefridus J. Peters

DOI:

https://doi.org/10.5599/admet.4.1.275

Abstract

Transport of erlotinib, gefitinib, sorafenib, sunitinib, dasatinib and crizotinib can be active or passive, which was studied by measuring uptake  at low (4 °C; passive) and normal temperature (37 °C; active and passive) and by the use of specific organic cation transporter (OCT) inhibitors. Intracellular accumulation was determined using Caco-2 as monolayers, while for gut permeation we used differentiated Caco-2 as model for intestinal epithelium in the Transwell system. Sorafenib and crizotinib uptake are likely to be dependent on passive transport. Gefitinib, dasatinib and sunitinib uptake seem to be active. Erlotinib’s transport also seems to be active. This study suggests that hOCTs might be involved in the apical to basolateral transport of gefitinib and crizotinib. Overall it can be concluded that the accumulation and transport of these six TKIs are very different, despite the fact that they are all tyrosine kinase inhibitors.

Downloads

Download data is not yet available.

Downloads

Published

30-03-2016

How to Cite

Honeywell, R. J., Hitzerd, S., Kathmann, I., & Peters, G. J. (2016). Transport of six tyrosine kinase inhibitors: active or passive?. ADMET and DMPK, 4(1), 23–34. https://doi.org/10.5599/admet.4.1.275

Issue

Section

Original Scientific Articles